OCCIDENT is excited to announce its participation in Tubulis’ € 128 million Series B2 round co-led by EQT Life Sciences and Nextech Invest alongside the new US-based funds Frazier Life Sciences and Deep Track Capital as well as existing investors including Andera Partners, Evotec, Fund+, Bayern Kapital (with ScaleUp-Fonds Bayern), BioMedPartners, coparion, High-Tech Gründerfonds (HTGF), and Seventure Partners.
Tubulis develops novel antibody drug conjugates aimed at the targeted and effective treatment of cancer and other diseases. The raised funds will be used to accelerate clinical development of Tubulis’ lead antibody drug candidates TUB-030 and TUB-040. TUB-030 is directed against the tumor-associated antigen 5T4 and addresses a wide range of solid tumor indications. TUB-040 targets Napi2b, a well-characterized target in ovarian and lung cancer. Both ADC candidates are optimized for long-lasting tumor engagement and minimal off-target toxicity.
Big congratulations to the whole team on this amazing success! We very much look forward to the next exciting steps in the company’s development.
More information in the press release under the following link.
More about Tubulis
